Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6640667 | 0.86 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1994949 | 0.84 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| Hydrochloric Acid SCHEMBL6640716 | 0.83 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2000094 | 0.82 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1993559 | 0.82 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1996585 | 0.80 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| Trifluoroacetic Acid SCHEMBL6643238 | 0.77 | TGFBR1 (0.55) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1995900 | 0.76 | TGFBR1 (0.60) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2001678 | 0.75 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| Hydrochloric Acid SCHEMBL6640025 | 0.75 | TGFBR1 (0.59) | MAPK14MAPK13MAPK12MAPK11PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.